0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical evaluation of code‐based algorithms to identify patients with pulmonary arterial hypertension in healthcare databases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pulmonary arterial hypertension (PAH) is a rare subgroup of pulmonary hypertension (PH). Claims and administrative databases can be particularly important for research in rare diseases; however, there is a lack of validated algorithms to identify PAH patients using administrative codes. We aimed to measure the accuracy of code‐based PAH algorithms against the true clinical diagnosis by right heart catheterization (RHC). This study evaluated algorithms in patients who were recorded in two linkable data assets: the Stanford Healthcare administrative electronic health record database and the Stanford Vera Moulton Wall Center clinical PH database (which records each patient's RHC diagnosis). We assessed the sensitivity and specificity achieved by 16 algorithms (six published). In total, 720 PH patients with linked data available were included and 558 (78%) of these were PAH patients. Algorithms consisting solely of a P(A)H‐specific diagnostic code classed all or almost all PH patients as PAH (sensitivity >97%, specificity <12%) while multicomponent algorithms with well‐defined temporal sequences of procedure, diagnosis and treatment codes achieved a better balance of sensitivity and specificity. Specificity increased and sensitivity decreased with increasing algorithm complexity. The best‐performing algorithms, in terms of fewest misclassified patients, included multiple components (e.g., PH diagnosis, PAH treatment, continuous enrollment for ≥6 months before and ≥12 months following index date) and achieved sensitivities and specificities of around 95% and 38%, respectively. Our findings help researchers tailor their choice and design of code‐based PAH algorithms to their research question and demonstrate the importance of including well‐defined temporal components in the algorithms.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: not found
          • Article: not found

          2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pulmonary arterial hypertension in France: results from a national registry.

            Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in a shared-care approach. To describe clinical and hemodynamic parameters and to provide estimates for the prevalence of patients diagnosed for PAH according to a standardized definition. The registry was initiated in 17 university hospitals following at least five newly diagnosed patients per year. All consecutive adult (> or = 18 yr) patients seen between October 2002 and October 2003 were to be included. A total of 674 patients (mean +/- SD age, 50 +/- 15 yr; range, 18-85 yr) were entered in the registry. Idiopathic, familial, anorexigen, connective tissue diseases, congenital heart diseases, portal hypertension, and HIV-associated PAH accounted for 39.2, 3.9, 9.5, 15.3, 11.3, 10.4, and 6.2% of the population, respectively. At diagnosis, 75% of patients were in New York Heart Association functional class III or IV. Six-minute walk test was 329 +/- 109 m. Mean pulmonary artery pressure, cardiac index, and pulmonary vascular resistance index were 55 +/- 15 mm Hg, 2.5 +/- 0.8 L/min/m(2), and 20.5 +/- 10.2 mm Hg/L/min/m(2), respectively. The low estimates of prevalence and incidence of PAH in France were 15.0 cases/million of adult inhabitants and 2.4 cases/million of adult inhabitants/yr. One-year survival was 88% in the incident cohort. This contemporary registry highlights current practice and shows that PAH is detected late in the course of the disease, with a majority of patients displaying severe functional and hemodynamic compromise.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Epidemiology and treatment of pulmonary arterial hypertension

              The epidemiology of pulmonary arterial hypertension (PAH) has evolved considerably in the past 2 decades. In this Review, Lau and colleagues describe how this evolving epidemiology has influenced the treatment and management of PAH.
                Bookmark

                Author and article information

                Contributors
                edidden@its.jnj.com
                Journal
                Pulm Circ
                Pulm Circ
                10.1002/(ISSN)2045-8940
                PUL2
                Pulmonary Circulation
                John Wiley and Sons Inc. (Hoboken )
                2045-8932
                2045-8940
                08 February 2024
                January 2024
                : 14
                : 1 ( doiID: 10.1002/pul2.v14.1 )
                : e12333
                Affiliations
                [ 1 ] Global Epidemiology, Rare Disease Epicenter, Actelion Pharmaceuticals Ltd Janssen Pharmaceutical Company of Johnson & Johnson Allschwil Switzerland
                [ 2 ] Quantitative Sciences Unit Stanford University Stanford California USA
                [ 3 ] Adult PH Program Vera Moulton Wall Center University Stanford California USA
                [ 4 ] Division of Pulmonary, Allergy, and Critical Care Medicine Stanford University Stanford California USA
                Author notes
                [*] [* ] Correspondence Eva‐Maria Didden, Actelion Pharmaceuticals Ltd, Janssen Pharmaceutical Company of Johnson & Johnson, Gewerbestrasse 16, CH‐4123 Allschwil, Switzerland.

                Email: edidden@ 123456its.jnj.com

                Author information
                http://orcid.org/0000-0001-7401-8877
                http://orcid.org/0000-0002-0757-7959
                Article
                PUL212333
                10.1002/pul2.12333
                10851026
                38333073
                c0f21215-2564-4079-9d9a-aa14f27e3e8e
                © 2024 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 24 November 2023
                : 14 September 2023
                : 21 December 2023
                Page count
                Figures: 2, Tables: 5, Pages: 14, Words: 7045
                Funding
                Funded by: Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                January 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.6 mode:remove_FC converted:08.02.2024

                Respiratory medicine
                administrative codes,clinical database,electronic health records,pulmonary arterial hypertension,pulmonary hypertension

                Comments

                Comment on this article